DORZOLAMIDE/TIMOLOL APOTEX 20/5 dorzolamide/timolol eye drops Australia - English - Department of Health (Therapeutic Goods Administration)

dorzolamide/timolol apotex 20/5 dorzolamide/timolol eye drops

arrotex pharmaceuticals pty ltd - timolol maleate, quantity: 6.8 mg/ml (equivalent: timolol, qty 5 mg); dorzolamide hydrochloride, quantity: 22.3 mg/ml (equivalent: dorzolamide, qty 20 mg) - eye drops, solution - excipient ingredients: mannitol; sodium citrate dihydrate; water for injections; benzalkonium chloride; sodium hydroxide; hyetellose - dorzolamide/timolol 20/5 eye drops are indicated in the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma when concomitant therapy is appropriate.

TIMOLOL MALEATE- timolol maleate solution/ drops United States - English - NLM (National Library of Medicine)

timolol maleate- timolol maleate solution/ drops

nucare pharmaceuticals,inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

TIMOLOL MALEATE- timolol maleate solution/ drops United States - English - NLM (National Library of Medicine)

timolol maleate- timolol maleate solution/ drops

nucare pharmaceuticals,inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic solution is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

TIMOLOL MLabs 0.25% timolol (as maleate) 2.5 mg/ mL eye drops solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

timolol mlabs 0.25% timolol (as maleate) 2.5 mg/ ml eye drops solution bottle

micro labs pty ltd - timolol maleate, quantity: 3.4 mg/ml (equivalent: timolol, qty 2.5 mg/ml) - eye drops, solution - excipient ingredients: sodium hydroxide; dibasic sodium phosphate dodecahydrate; benzalkonium chloride; water for injections; monobasic sodium phosphate dihydrate - timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure.,in clinical trials it has been shown to reduce intraocular pressure in:,patients with ocular hypertension,patients with chronic open-angle glaucoma,aphakic patients with glaucoma.

TIMOLOL MLabs 0.5% timolol (as maleate) 5 mg/mL eye drops solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

timolol mlabs 0.5% timolol (as maleate) 5 mg/ml eye drops solution bottle

micro labs pty ltd - timolol maleate, quantity: 6.8 mg/ml (equivalent: timolol, qty 5 mg/ml) - eye drops, solution - excipient ingredients: water for injections; monobasic sodium phosphate dihydrate; sodium hydroxide; dibasic sodium phosphate dodecahydrate; benzalkonium chloride - timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure.,in clinical trials it has been shown to reduce intraocular pressure in:,patients with ocular hypertension,patients with chronic open-angle glaucoma,aphakic patients with glaucoma

TIMOLOL B&B 0.25% timolol (as maleate) 2.5 mg/mL eye drops solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

timolol b&b 0.25% timolol (as maleate) 2.5 mg/ml eye drops solution bottle

micro labs pty ltd - timolol maleate, quantity: 3.4 mg/ml (equivalent: timolol, qty 2.5 mg/ml) - eye drops, solution - excipient ingredients: water for injections; dibasic sodium phosphate dodecahydrate; sodium hydroxide; monobasic sodium phosphate dihydrate; benzalkonium chloride - timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure.,in clinical trials it has been shown to reduce intraocular pressure in:,patients with ocular hypertension,patients with chronic open-angle glaucoma,aphakic patients with glaucoma.

TIMOLOL MLPL 0.25%  timolol (as maleate) 2.5 mg/mL eye drops solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

timolol mlpl 0.25% timolol (as maleate) 2.5 mg/ml eye drops solution bottle

micro labs pty ltd - timolol maleate, quantity: 3.4 mg/ml (equivalent: timolol, qty 2.5 mg/ml) - eye drops, solution - excipient ingredients: benzalkonium chloride; dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; sodium hydroxide; water for injections - timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure.,in clinical trials it has been shown to reduce intraocular pressure in:,patients with ocular hypertension,patients with chronic open-angle glaucoma,aphakic patients with glaucoma.

TIMOLOL MLPL 0.5% timolol (as maleate) 5 mg/mL eye drops solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

timolol mlpl 0.5% timolol (as maleate) 5 mg/ml eye drops solution bottle

micro labs pty ltd - timolol maleate, quantity: 6.8 mg/ml (equivalent: timolol, qty 5 mg/ml) - eye drops, solution - excipient ingredients: benzalkonium chloride; water for injections; dibasic sodium phosphate dodecahydrate; sodium hydroxide; monobasic sodium phosphate dihydrate - timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure.,in clinical trials it has been shown to reduce intraocular pressure in:,patients with ocular hypertension,patients with chronic open-angle glaucoma,aphakic patients with glaucoma